Iovance Biotherapeutics/$IOVA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Iovance Biotherapeutics
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
Ticker
$IOVA
Sector
Primary listing
Employees
838
Headquarters
Website
IOVA Metrics
BasicAdvanced
$792M
-
-$1.23
0.82
-
Price and volume
Market cap
$792M
Beta
0.82
52-week high
$12.10
52-week low
$1.64
Average daily volume
11M
Financial strength
Current ratio
3.271
Quick ratio
2.796
Long term debt to equity
6.456
Total debt to equity
7.612
Profitability
EBITDA (TTM)
-376.294
Gross margin (TTM)
20.60%
Net profit margin (TTM)
-161.44%
Operating margin (TTM)
-170.02%
Effective tax rate (TTM)
-0.05%
Revenue per employee (TTM)
$290,000
Management effectiveness
Return on assets (TTM)
-27.42%
Return on equity (TTM)
-53.16%
Valuation
Price to revenue (TTM)
2.87
Price to book
1.07
Price to tangible book (TTM)
1.86
Price to free cash flow (TTM)
-2.142
Free cash flow yield (TTM)
-46.68%
Free cash flow per share (TTM)
-1.022
Growth
Revenue change (TTM)
636.99%
Earnings per share change (TTM)
-26.30%
3-year earnings per share growth (CAGR)
-19.95%
10-year earnings per share growth (CAGR)
8.18%
What the Analysts think about IOVA
Analyst ratings (Buy, Hold, Sell) for Iovance Biotherapeutics stock.
Bulls say / Bears say
Iovance is expanding its iCTC manufacturing campus to support the production of TIL therapies for over 5,000 patients annually. The company is also developing a wider network able to serve more than 10,000 patients each year, placing it in a strong position to meet growing worldwide demand (GlobeNewswire).
Currently, the company holds about 280 granted or allowed U.S. and international patents covering Amtagvi and related TIL technologies, securing market exclusivity at least until 2042 and strengthening its position in the TIL cell therapy field (GlobeNewswire).
Iovance has submitted marketing authorization applications for lifileucel (Amtagvi) in the UK, EU, and Canada, with all applications accepted for review. Approvals expected in 2025 could enable access to more than 20,000 advanced melanoma patients outside the U.S. each year (GlobeNewswire).
Iovance’s first-quarter 2025 product revenue was $49.3 million, falling over 40% short of analyst expectations. As a result, the company cut its full-year 2025 revenue guidance from $450–475 million down to $250–300 million, signaling that Amtagvi’s commercial adoption has been weaker than expected (Investing.com).
The company plans to reduce its workforce by 19% in Q3 2025 to save more than $100 million annually, a cost-cutting move in response to sluggish sales, which will only extend its cash runway until Q4 2026 (BioPharma Dive).
Iovance reported a net loss of $116.2 million in Q1 2025 due to elevated operating expenses and limited capacity during scheduled maintenance, pointing to ongoing risk of high cash burn despite existing cash reserves (GuruFocus).
Data summarised monthly by Lightyear AI. Last updated on 1 Oct 2025.
IOVA Financial Performance
Revenues and expenses
IOVA Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Iovance Biotherapeutics stock?
Iovance Biotherapeutics (IOVA) has a market cap of $792M as of October 24, 2025.
What is the P/E ratio for Iovance Biotherapeutics stock?
The price to earnings (P/E) ratio for Iovance Biotherapeutics (IOVA) stock is 0 as of October 24, 2025.
Does Iovance Biotherapeutics stock pay dividends?
No, Iovance Biotherapeutics (IOVA) stock does not pay dividends to its shareholders as of October 24, 2025.
When is the next Iovance Biotherapeutics dividend payment date?
Iovance Biotherapeutics (IOVA) stock does not pay dividends to its shareholders.
What is the beta indicator for Iovance Biotherapeutics?
Iovance Biotherapeutics (IOVA) has a beta rating of 0.82. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.